Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Rani Therapeutics Holdings, Inc.

RANI · Nasdaq · CIK 0001856725 · Healthcare · Biotechnology

INSIDER SIGNAL

44.6 / 100

2 buyers · 2 purchase transaction lines · $50.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+5.3 / 25
Role+13.0 / 20
Recency+2.3 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Imran TalatChief Executive Officer
○●○
Javadi AlirezaChief Technical Officer
○○
IMRAN MIR ADirector,TenPercentOwner
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION50%Largest buyer: Imran Talat · $25.2K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-07-17–2026-07-21

Roles in the peak window: Chief Executive Officer, Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

44.6 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 44.9
  2. 44.8
  3. 44.7
  4. 44.6
  5. 44.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

3Purchases
3Sales
7Other Form 4 lines
8SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER4 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-2.8%
3M
+26.2%
6M
+8.0%
12M
+63.1%

Volatility & liquidity

Volatility
210.8%
Beta
—
Avg daily value
USD 582,307

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-89.9%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
7,249,790
Previous report
7,116,584
Avg daily volume
624,094
Days to cover
11.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-21IMRAN MIR APurchase (P)Class A Common Stock36,000USD 0.69USD 24,840SEC filing ↗
2026-07-17Imran TalatPurchase (P)Class A Common Stock35,000USD 0.72USD 25,200SEC filing ↗
2025-10-23IMRAN MIR APurchase (P)Class A Common Stock2,083,334USD 0.61USD 1,270,834SEC filing ↗
2024-12-13McKinley KatePurchase (P)Class A Common Stock17,960USD 1.67USD 29,993SEC filing ↗
2024-12-09Imran TalatPurchase (P)Class A Common Stock10,296USD 1.94USD 19,974SEC filing ↗
2023-12-06Imran TalatPurchase (P)Class A Common Stock10,000USD 2.27USD 22,700SEC filing ↗
2023-12-04Imran TalatPurchase (P)Class A Common Stock5,000USD 2.57USD 12,850SEC filing ↗
2023-11-29Imran TalatPurchase (P)Class A Common Stock20,000USD 2.05USD 41,000SEC filing ↗
2023-11-24South Cone Investments Limited Partnership; South Lake One LLCPurchase (P)Class A Common Stock5,265,165USD 2.01USD 10,582,982SEC filing ↗
2023-11-17BUTEL JEAN LUCPurchase (P)Class A Common Stock50,500USD 2.03USD 102,515SEC filing ↗
2023-11-16Nanavaty MaulikPurchase (P)Class A Common Stock500USD 1.98USD 990SEC filing ↗
2023-11-07Imran TalatPurchase (P)Class A Common Stock5,000USD 2.00USD 9,975SEC filing ↗
2023-05-12South Cone Investments Limited Partnership; South Lake One LLCPurchase (P)Class A Common Stock2,645USD 3.98USD 10,527SEC filing ↗
2023-05-11South Cone Investments Limited Partnership; South Lake One LLCPurchase (P)Class A Common Stock2,610USD 3.87USD 10,101SEC filing ↗
2023-05-08South Cone Investments Limited Partnership; South Lake One LLCPurchase (P)Class A Common Stock4,420USD 4.46USD 19,713SEC filing ↗

Form 4 evidence

13 transaction lines in the latest 365-day window; 141 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-27Javadi AlirezaTax withholding (F)Class A Common Stock309USD 0.76USD 235SEC filing ↗
2026-09-27Imran TalatTax withholding (F)Class A Common Stock7,928USD 0.76USD 6,025SEC filing ↗
2026-07-21IMRAN MIR APurchase (P)Class A Common Stock36,000USD 0.69USD 24,840SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-27Javadi AlirezaTax withholding (F)Class A Common Stock309USD 0.76USD 235SEC filing ↗
2026-09-27Imran TalatTax withholding (F)Class A Common Stock7,928USD 0.76USD 6,025SEC filing ↗
2026-07-21IMRAN MIR APurchase (P)Class A Common Stock36,000USD 0.69USD 24,840SEC filing ↗
2026-07-17Imran TalatPurchase (P)Class A Common Stock35,000USD 0.72USD 25,200SEC filing ↗
2026-06-27Javadi AlirezaTax withholding (F)Class A Common Stock309USD 0.74USD 229SEC filing ↗
2026-06-27Imran TalatTax withholding (F)Class A Common Stock7,927USD 0.74USD 5,866SEC filing ↗
2026-03-27Javadi AlirezaSale (S)Class A Common Stock386USD 0.78USD 301SEC filing ↗
2026-03-27Imran TalatTax withholding (F)Class A Common Stock9,099USD 0.81USD 7,370SEC filing ↗
2026-03-22Imran TalatTax withholding (F)Class A Common Stock8,916USD 1.13USD 10,075SEC filing ↗
2025-12-27Imran TalatTax withholding (F)Class A Common Stock7,906USD 1.40USD 11,068SEC filing ↗
2025-10-23IMRAN MIR APurchase (P)Class A Common Stock2,083,334USD 0.61USD 1,270,834SEC filing ↗
2025-10-21South Cone Investments Limited PartnershipSale (S)Class A Common Stock4,000,000USD 2.77USD 11,080,000SEC filing ↗
2025-10-20South Cone Investments Limited PartnershipSale (S)Class A Common Stock1,923,000USD 2.41USD 4,634,430SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerRANI
CIK0001856725
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history141 transaction lines from 2021-07-30 to 2026-09-27
87 P purchase lines · 11 S sale lines · 43 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.